1. Home
  2. WGSWW vs PNRG Comparison

WGSWW vs PNRG Comparison

Compare WGSWW & PNRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WGSWW
  • PNRG
  • Stock Information
  • Founded
  • WGSWW 2017
  • PNRG 1973
  • Country
  • WGSWW United States
  • PNRG United States
  • Employees
  • WGSWW 1000
  • PNRG N/A
  • Industry
  • WGSWW Retail: Computer Software & Peripheral Equipment
  • PNRG Oil & Gas Production
  • Sector
  • WGSWW Technology
  • PNRG Energy
  • Exchange
  • WGSWW Nasdaq
  • PNRG Nasdaq
  • Market Cap
  • WGSWW N/A
  • PNRG N/A
  • IPO Year
  • WGSWW N/A
  • PNRG N/A
  • Fundamental
  • Price
  • WGSWW $0.05
  • PNRG $169.69
  • Analyst Decision
  • WGSWW
  • PNRG
  • Analyst Count
  • WGSWW 0
  • PNRG 0
  • Target Price
  • WGSWW N/A
  • PNRG N/A
  • AVG Volume (30 Days)
  • WGSWW 36.6K
  • PNRG 16.4K
  • Earning Date
  • WGSWW 02-18-2025
  • PNRG 05-16-2025
  • Dividend Yield
  • WGSWW N/A
  • PNRG N/A
  • EPS Growth
  • WGSWW N/A
  • PNRG 103.81
  • EPS
  • WGSWW N/A
  • PNRG 21.95
  • Revenue
  • WGSWW $305,450,000.00
  • PNRG $234,078,000.00
  • Revenue This Year
  • WGSWW N/A
  • PNRG N/A
  • Revenue Next Year
  • WGSWW N/A
  • PNRG N/A
  • P/E Ratio
  • WGSWW N/A
  • PNRG $7.80
  • Revenue Growth
  • WGSWW 50.79
  • PNRG 89.47
  • 52 Week Low
  • WGSWW $0.17
  • PNRG $100.22
  • 52 Week High
  • WGSWW $0.21
  • PNRG $243.49
  • Technical
  • Relative Strength Index (RSI)
  • WGSWW N/A
  • PNRG 43.34
  • Support Level
  • WGSWW N/A
  • PNRG $159.73
  • Resistance Level
  • WGSWW N/A
  • PNRG $174.01
  • Average True Range (ATR)
  • WGSWW 0.00
  • PNRG 7.49
  • MACD
  • WGSWW 0.00
  • PNRG 0.66
  • Stochastic Oscillator
  • WGSWW 0.00
  • PNRG 34.54

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Share on Social Networks: